查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1998363

血液篩檢市場：按檢測類型、技術、檢體類型、檢測模式和最終用戶分類的全球市場預測，2026-2032年

Blood Screening Market by Test Type, Technology, Sample Type, Testing Mode, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 187 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，血液篩檢市場價值將達到 57.9 億美元，到 2026 年將成長至 63.1 億美元，到 2032 年將達到 106.4 億美元，複合年成長率為 9.07%。

主要市場統計數據
基準年 2025 57.9億美元
預計年份：2026年 63.1億美元
預測年份 2032 106.4億美元
複合年成長率 (%) 9.07%

權威的介紹概述了診斷技術、工作流程要求和監管期望如何相互交織，從而重塑整個醫療保健系統的血液篩檢策略。

血液篩檢目前正處於關鍵轉折點，在臨床期望、更嚴格的監管和技術進步的共同推動下，輸血安全和感染疾病監測的管理方式正在改變。診斷靈敏度和特異性的提高使得早期發現成為可能，而檢查室工作流程的整合和自動化則縮短了周轉時間並減少了實驗室負責人之間的差異。同時，人們對捐血安全、病原體出現和供應鏈韌性的擔憂日益加劇，促使相關人員重新評估檢測流程和籌資策略。

簡要分析正在重塑醫療保健機構血液篩檢工作流程和供應商合作的關鍵技術、監管和營運變革。

近年來，在技術創新和不斷變化的臨床需求的驅動下，血液篩檢領域發生了翻天覆地的變化。即時檢測（POC​​）技術日益成熟，減少了對中心檢查室在某些快速篩檢需求上的依賴；同時，檢查室平台也正在整合先進的自動化和數據整合技術，以滿足對處理能力和可追溯性的需求。此外，分子診斷技術正從小眾應用走向更廣泛的應用，從而能夠更精準地檢測病原體和識別變異株。

對 2025 年實施的美國關稅調整的累積營運和採購影響以及相關人員。

美國2025年實施的政策變化，包括關稅調整，為診斷產業相關人員的採購和供應鏈規劃帶來了新的考量。關稅調整凸顯了籌資策略的重要性，這些策略應優先考慮本地製造、延長關鍵耗材的前置作業時間，並實現供應商多元化，以降低進口成本波動帶來的風險。這些措施也會影響供應商的路線選擇和庫存策略，促使人們更加關注單價以外的總到岸成本（TLC）。

從詳細的分割觀點展示了測試類型、技術模式、最終用戶環境、檢體處理和測試模式如何相互作用，從而影響診斷設備的選擇和實施。

細分分析揭示了臨床需求和操作環境的差異如何影響不同檢測類型、技術、最終用戶、檢體類型和檢測模式的部署模式。即使在同一檢測類型中，B型肝炎、C型肝炎、愛滋病毒和梅毒的篩檢在靈敏度、窗口期和確診檢測方面也各有其獨特的挑戰，從而影響演算法設計和複檢路徑。因此，診斷平台必須使分析效能與確診檢測和捐血者諮詢等實際需求相符。

一份策略性區域分析報告，詳細闡述了醫療保健基礎設施、管理體制和生產能力如何決定世界各地不同的血液篩檢優先事項。

區域趨勢反映了醫療基礎設施、政策重點和製造業生態系統，並以不同的方式影響技術採納、監管流程和籌資策略。在美洲，大規模綜合醫療系統和集中式血液服務往往傾向於採用高通量檢測平台和全面的品管體系，同時也支持在分散式環境中開展檢查室檢測與就地檢驗的創新試點計畫。報銷機制和國家指南進一步指導篩檢演算法的實施和推廣。

這份重點突出的商業洞察報告概述了供應商如何透過平台創新、服務模式和策略夥伴關係關係實現差異化，從而獲得長期成功和廣泛應用。

血液篩檢領域的競爭格局涵蓋平台創新、試劑組合、服務模式和監管互動。主要企業透過投資自動化、數位化連接和提供廣泛的檢測項目來脫穎而出，既服務於高通量血庫環境，也服務於分散的照護現場。這些企業也正在不斷完善售後服務，例如遠端診斷支援、耗材管理和培訓項目，以提高客戶維繫並減少終端用戶的操作障礙。

為確保篩檢計畫的未來可行性，向高階主管提出具體建議，以增強診斷柔軟性、供應彈性、數位整合、人才儲備和協作檢驗。

產業領導者應優先考慮一系列切實可行的措施，以平衡臨床卓越性、營運韌性和商業性靈活性。首先，在採購決策中融入模組化理念，選擇支援分階段升級和多項檢測的平台，從而降低長期供應商鎖定風險，並保持柔軟性以適應不斷變化的檢測需求。其次，投資於供應鏈多元化和合約條款，以抵禦地緣政治因素和關稅波動的影響，同時確保關鍵耗材的持續供應。

透過結合相關利益者訪談、監管指導審查和技術評估，我們採用透明的、基於三角測量的調查方法，為決策者提供具體的見解。

這份綜合報告採用三角驗證調查方法，結合對關鍵相關人員的訪談、對通訊協定和監管指南的審查以及系統的技術評估，得出了可靠的見解。主要活動包括與實驗室主任、輸血醫學專家、採購經理和診斷設備供應商進行對話，以確定實際限制因素、推廣應用促進因素和實施結果。為了補充這些定性訊息，報告還系統地審查了公開的監管指南、臨床檢驗報告和設備標籤檢視，檢驗性能聲明和核准流程要求。

明確且可操作的結論強調實證實施、供應鏈韌性和數位化整合是永續血液篩檢計畫的支柱。

血液篩檢處於臨床需求與技術潛力的交匯點，迫使相關人員謹慎選擇，以平衡分析績效與營運限制。新的工具和更完善的連接性帶來了許多機遇，例如縮短檢測時間、簡化工作流程和增強可追溯性，但成功實施需要根據當地的基礎設施、人員能力和供應鏈實際情況制定個性化的部署策略。因此，決策者應優先考慮兼具臨床價值和營運可行性的解決方案。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 血液篩檢市場：檢測類型

  • 乙型肝炎篩檢
  • 丙型肝炎篩檢
  • 愛滋病毒篩檢
  • 梅毒篩檢

第9章 血液篩檢市場：依技術分類

  • 化學冷光
  • 流式細胞技術
  • 免疫檢測
    • 化學冷光免疫檢測
    • 酵素免疫分析法
    • 免疫測量
  • 分子診斷
    • 等溫擴增
    • 次世代定序
    • 聚合酵素鏈鎖反應

第10章檢體類型分類的血液篩檢市場

  • 電漿
  • 血清
  • 全血

第11章 依檢測模式分類的血液篩檢市場

  • 檢查室基地
  • 照護端

第12章 血液篩檢市場：依最終用戶分類

  • 血庫
  • 診所
  • 診斷檢測實驗室
  • 醫院

第13章 血液篩檢市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章 血液篩檢市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 血液篩檢市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章：美國血液篩檢市場

第17章：中國血液篩檢市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Abbott Laboratories
  • Becton, Dickinson and Company
  • Bio-Rad Laboratories, Inc.
  • bioMerieux SA
  • Danaher Corporation
  • F. Hoffmann-La Roche Ltd
  • Grifols, SA
  • Hologic, Inc.
  • Merck KGaA
  • Ortho Clinical Diagnostics, Inc.
  • QIAGEN NV
  • Siemens Healthineers AG
  • Terumo BCT, Inc.
  • Thermo Fisher Scientific Inc.
Product Code: MRR-374DB5A06BE3

The Blood Screening Market was valued at USD 5.79 billion in 2025 and is projected to grow to USD 6.31 billion in 2026, with a CAGR of 9.07%, reaching USD 10.64 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 5.79 billion
Estimated Year [2026] USD 6.31 billion
Forecast Year [2032] USD 10.64 billion
CAGR (%) 9.07%

An authoritative introduction framing how diagnostics, workflow imperatives, and regulatory expectation intersect to reshape blood screening strategy across healthcare systems

The landscape of blood screening is at a pivotal juncture where clinical expectation, regulatory rigor, and technological capability converge to redefine how transfusion safety and infectious disease surveillance are managed. Advances in diagnostic sensitivity and specificity are enabling earlier detection windows, while integrated laboratory workflows and automation are reducing turnaround times and operator variability. These developments are occurring alongside heightened attention to donor safety, pathogen emergence, and supply chain resilience, prompting stakeholders to reassess testing algorithms and procurement strategies.

Healthcare leaders must now balance clinical performance with operational realities, including staffing limitations, infrastructure constraints, and the need for standardized result interpretation across decentralized settings. At the same time, the design and deployment of testing platforms are increasingly influenced by cross-disciplinary priorities such as data interoperability, quality management, and cost containment. In this context, a clear-eyed introduction lays the foundation for understanding how diagnostic modalities, testing modes, and end-user environments interact to shape practical decision-making in blood screening programs.

A concise exploration of pivotal technological, regulatory, and operational shifts that are reshaping blood screening workflows and supplier engagement across care settings

Over recent years the blood screening landscape has experienced transformative shifts driven by technological innovation and evolving clinical imperatives. Point-of-care capabilities have matured, reducing the dependence on centralized laboratories for certain rapid screening needs, while laboratory-based platforms have embraced higher degrees of automation and data connectivity to meet throughput and traceability demands. Concurrently, molecular diagnostics have moved from niche applications toward broader operational integration, enabling more precise pathogen detection and variant discrimination.

These shifts have also produced changes in procurement behavior and vendor engagement models. Health systems are increasingly seeking solutions that deliver not only diagnostic performance but also lifecycle support, remote monitoring, and seamless integration with laboratory information systems. Regulatory agencies are clarifying pathways for novel assays and platforms, which in turn affects adoption timelines. Looking ahead, interoperability and modularity will be central to platform selection as institutions prioritize flexibility to respond to emergent threats and evolving screening protocols.

An analytical review of the cumulative operational and procurement impacts generated by United States tariff adjustments enacted in 2025 and how stakeholders adapted

Policy changes, including tariff adjustments implemented in the United States in 2025, have introduced new considerations into procurement and supply chain planning for diagnostic stakeholders. Tariff realignment has increased the prominence of sourcing strategies that prioritize regional manufacturing, longer lead times for critical consumables, and diversification of supplier bases to mitigate exposure to import-related cost volatility. These measures also influenced vendor routing decisions and inventory policies, prompting a closer examination of total landed cost beyond unit pricing.

In practice, laboratory managers and procurement teams responded by enhancing demand forecasting, revising reorder thresholds, and engaging in strategic partnerships with suppliers capable of local production or preferential distribution agreements. The downstream impacts extended to capital equipment procurement cycles as organizations evaluated tradeoffs between upfront investment and recurring consumable dependencies. Overall, the 2025 tariff environment underscored the necessity for agile supply chain governance, scenario planning, and contractual provisions that address geopolitical and policy-driven disruptions.

A nuanced segmentation-driven perspective showing how test type, technology modality, end-user setting, sample handling, and testing mode jointly inform diagnostic selection and deployment

Segmentation analysis illuminates how differentiated clinical needs and operational contexts drive adoption patterns across test types, technologies, end users, sample types, and testing modes. Within test types, screening for Hepatitis B, Hepatitis C, HIV, and Syphilis each carries distinct sensitivity, window-period, and confirmatory testing implications that affect algorithm design and reflex testing pathways. Diagnostic platforms must therefore align analytical performance with practical requirements for confirmatory follow-up and donor counselling.

Technology segmentation further clarifies capability tradeoffs: chemiluminescence delivers high-throughput signal detection while flow cytometry supports multi-parametric analysis for certain immunologic assessments. Immunoassays span chemiluminescence immunoassay, enzyme linked immunosorbent assay, and radioimmunoassay formats, each presenting different reagent stability, automation compatibility, and cost profiles. Molecular diagnostics encompass isothermal amplification, next generation sequencing, and polymerase chain reaction methods, offering varying balances of speed, sensitivity, and information depth. End-user contexts-blood banks, clinics, diagnostic laboratories, and hospitals-shape workflow integration, staff competencies, and accreditation requirements. Sample type considerations including plasma, serum, and whole blood influence pre-analytical handling and test selection, while testing mode choices between lab-based and point-of-care approaches determine where testing occurs and how results are actioned operationally. Together, these segmentation lenses provide a practical framework for pairing clinical aims with appropriate diagnostic solutions.

A strategic regional analysis detailing how healthcare infrastructure, regulatory regimes, and manufacturing capacity drive divergent blood screening priorities across global regions

Regional dynamics influence technology adoption, regulatory pathways, and procurement strategies in distinct ways that reflect healthcare infrastructure, policy priorities, and manufacturing ecosystems. In the Americas, large integrated health systems and centralized blood services tend to favor high-throughput laboratory platforms and comprehensive quality frameworks, while also supporting innovation pilots that bridge laboratory and point-of-care testing for decentralized contexts. Reimbursement structures and national guidelines further guide how screening algorithms are implemented and scaled.

Europe, Middle East & Africa present a heterogeneous environment where regulatory harmonization efforts coexist with variable infrastructure capacities; some markets emphasize stringency and full traceability, whereas others prioritize affordable, robust solutions suited to constrained settings. In the Asia-Pacific region, rapid modernization of laboratory networks, local manufacturing capacity, and investments in molecular diagnostics are accelerating adoption of advanced platforms, with particular emphasis on scalability and supply chain localization. Awareness of these regional distinctions helps vendors and health systems tailor commercial strategies and implementation plans to local needs and regulatory realities.

A focused corporate insight outlining how suppliers are differentiating through platform innovation, service models, and strategic partnerships to win longevity and adoption

Competitive dynamics among companies operating in blood screening span platform innovation, reagent portfolios, service models, and regulatory engagement. Leading suppliers are differentiating through investments in automation, digital connectivity, and assay breadth to serve both high-throughput blood bank environments and decentralized point-of-care settings. These firms are also refining aftermarket offerings-including remote diagnostics support, consumable management, and training programs-to increase customer retention and reduce operational friction for end users.

Partnerships and co-development arrangements with clinical laboratories, academic centers, and manufacturing partners are increasingly common as companies seek to accelerate validation pathways and localize production. Strategic focus areas for market participants include improving turnaround times, reducing sample volume requirements, and enhancing multiplexing capabilities to consolidate testing workflows. Vendors that demonstrate clear evidence of clinical utility, operational reliability, and robust post-sales support are more likely to secure long-term procurement commitments from healthcare providers and blood services.

Concrete recommendations for executives to enhance diagnostic flexibility, supply resilience, digital integration, workforce readiness, and collaborative validation to future-proof screening programs

Industry leaders should prioritize a set of actionable measures that balance clinical excellence with operational resilience and commercial agility. First, embed modularity into procurement decisions by selecting platforms that allow incremental upgrades and multi-assay support to reduce long-term vendor lock-in and preserve flexibility as testing needs evolve. Second, invest in supply chain diversification and contractual clauses that protect against geopolitical and tariff-driven disruptions while ensuring continuity of critical consumables.

Third, accelerate integration of digital connectivity and laboratory information systems to improve result traceability, quality oversight, and interoperability across care settings. Fourth, develop clear adoption roadmaps that pair laboratory validation with staff training and confirmatory testing pathways so new technologies can be scaled without compromising safety. Finally, pursue collaborative pilot programs with public health agencies and donor organizations to validate novel testing protocols in real-world environments. These steps will help organizations manage risk, optimize operational performance, and sustain screening quality over time.

A transparent, tri-angulated research methodology combining stakeholder interviews, regulatory guidance review, and technology assessment to produce actionable insights for decision makers

This research synthesis draws on a triangulated methodology combining primary stakeholder interviews, protocol and regulatory guidance review, and systematic technology assessment to produce robust insights. Primary engagements included conversations with laboratory directors, transfusion medicine specialists, procurement leaders, and diagnostics vendors to surface practical constraints, adoption drivers, and implementation experiences. These qualitative inputs were supplemented by a structured review of public regulatory guidance, clinical validation reports, and device labeling to verify performance claims and pathway requirements.

Technology assessments evaluated analytical principles, operational characteristics, and interoperability features across platform types. Supply chain analysis examined manufacturing footprints, distribution channels, and tariff-sensitive procurement dependencies to understand risk vectors. Throughout the process, evidence was contextualized to reflect regional regulatory environments and typical end-user operational models. Findings were synthesized to emphasize actionable implications rather than abstract projections, and to support strategic decision-making for clinical, operational, and commercial stakeholders.

A clear and practical conclusion emphasizing evidence-driven adoption, supply chain resilience, and digital integration as the pillars of sustainable blood screening programs

Blood screening stands at the intersection of clinical necessity and technological possibility, requiring stakeholders to make disciplined choices that reconcile analytical performance with operational constraints. Emerging tools and enhanced connectivity offer opportunities to shorten detection windows, simplify workflows, and improve traceability, but successful adoption depends on tailored implementation strategies that reflect local infrastructure, staff competencies, and supply chain realities. Decision makers should therefore prioritize solutions that deliver both clinical value and operational viability.

In essence, the imperative is to adopt a pragmatic, evidence-driven approach: validate platforms within the context of intended use, strengthen supply chain governance to withstand policy shifts, and integrate digital workflows that support quality and interoperability. By doing so, healthcare organizations and diagnostic providers can ensure that blood screening systems are not only technologically advanced but also resilient, scalable, and closely aligned to patient safety objectives.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Blood Screening Market, by Test Type

  • 8.1. Hepatitis B Screening
  • 8.2. Hepatitis C Screening
  • 8.3. HIV Screening
  • 8.4. Syphilis Screening

9. Blood Screening Market, by Technology

  • 9.1. Chemiluminescence
  • 9.2. Flow Cytometry
  • 9.3. Immunoassays
    • 9.3.1. Chemiluminescence Immunoassay
    • 9.3.2. Enzyme Linked Immunosorbent Assay
    • 9.3.3. Radioimmunoassay
  • 9.4. Molecular Diagnostics
    • 9.4.1. Isothermal Amplification
    • 9.4.2. Next Generation Sequencing
    • 9.4.3. Polymerase Chain Reaction

10. Blood Screening Market, by Sample Type

  • 10.1. Plasma
  • 10.2. Serum
  • 10.3. Whole Blood

11. Blood Screening Market, by Testing Mode

  • 11.1. Lab Based
  • 11.2. Point Of Care

12. Blood Screening Market, by End User

  • 12.1. Blood Banks
  • 12.2. Clinics
  • 12.3. Diagnostic Laboratories
  • 12.4. Hospitals

13. Blood Screening Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Blood Screening Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Blood Screening Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Blood Screening Market

17. China Blood Screening Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Abbott Laboratories
  • 18.6. Becton, Dickinson and Company
  • 18.7. Bio-Rad Laboratories, Inc.
  • 18.8. bioMerieux SA
  • 18.9. Danaher Corporation
  • 18.10. F. Hoffmann-La Roche Ltd
  • 18.11. Grifols, S.A.
  • 18.12. Hologic, Inc.
  • 18.13. Merck KGaA
  • 18.14. Ortho Clinical Diagnostics, Inc.
  • 18.15. QIAGEN N.V.
  • 18.16. Siemens Healthineers AG
  • 18.17. Terumo BCT, Inc.
  • 18.18. Thermo Fisher Scientific Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL BLOOD SCREENING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL BLOOD SCREENING MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL BLOOD SCREENING MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL BLOOD SCREENING MARKET SIZE, BY TEST TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL BLOOD SCREENING MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL BLOOD SCREENING MARKET SIZE, BY SAMPLE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL BLOOD SCREENING MARKET SIZE, BY TESTING MODE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL BLOOD SCREENING MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL BLOOD SCREENING MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL BLOOD SCREENING MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL BLOOD SCREENING MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES BLOOD SCREENING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA BLOOD SCREENING MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL BLOOD SCREENING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL BLOOD SCREENING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL BLOOD SCREENING MARKET SIZE, BY HEPATITIS B SCREENING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL BLOOD SCREENING MARKET SIZE, BY HEPATITIS B SCREENING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL BLOOD SCREENING MARKET SIZE, BY HEPATITIS B SCREENING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL BLOOD SCREENING MARKET SIZE, BY HEPATITIS C SCREENING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL BLOOD SCREENING MARKET SIZE, BY HEPATITIS C SCREENING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL BLOOD SCREENING MARKET SIZE, BY HEPATITIS C SCREENING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL BLOOD SCREENING MARKET SIZE, BY HIV SCREENING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL BLOOD SCREENING MARKET SIZE, BY HIV SCREENING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL BLOOD SCREENING MARKET SIZE, BY HIV SCREENING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL BLOOD SCREENING MARKET SIZE, BY SYPHILIS SCREENING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL BLOOD SCREENING MARKET SIZE, BY SYPHILIS SCREENING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL BLOOD SCREENING MARKET SIZE, BY SYPHILIS SCREENING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL BLOOD SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL BLOOD SCREENING MARKET SIZE, BY CHEMILUMINESCENCE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL BLOOD SCREENING MARKET SIZE, BY CHEMILUMINESCENCE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL BLOOD SCREENING MARKET SIZE, BY CHEMILUMINESCENCE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL BLOOD SCREENING MARKET SIZE, BY FLOW CYTOMETRY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL BLOOD SCREENING MARKET SIZE, BY FLOW CYTOMETRY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL BLOOD SCREENING MARKET SIZE, BY FLOW CYTOMETRY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL BLOOD SCREENING MARKET SIZE, BY IMMUNOASSAYS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL BLOOD SCREENING MARKET SIZE, BY IMMUNOASSAYS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL BLOOD SCREENING MARKET SIZE, BY IMMUNOASSAYS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL BLOOD SCREENING MARKET SIZE, BY IMMUNOASSAYS, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL BLOOD SCREENING MARKET SIZE, BY CHEMILUMINESCENCE IMMUNOASSAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL BLOOD SCREENING MARKET SIZE, BY CHEMILUMINESCENCE IMMUNOASSAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL BLOOD SCREENING MARKET SIZE, BY CHEMILUMINESCENCE IMMUNOASSAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL BLOOD SCREENING MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL BLOOD SCREENING MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL BLOOD SCREENING MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL BLOOD SCREENING MARKET SIZE, BY RADIOIMMUNOASSAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL BLOOD SCREENING MARKET SIZE, BY RADIOIMMUNOASSAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL BLOOD SCREENING MARKET SIZE, BY RADIOIMMUNOASSAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL BLOOD SCREENING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL BLOOD SCREENING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL BLOOD SCREENING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL BLOOD SCREENING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL BLOOD SCREENING MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL BLOOD SCREENING MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL BLOOD SCREENING MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL BLOOD SCREENING MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL BLOOD SCREENING MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL BLOOD SCREENING MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL BLOOD SCREENING MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL BLOOD SCREENING MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL BLOOD SCREENING MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL BLOOD SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL BLOOD SCREENING MARKET SIZE, BY PLASMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL BLOOD SCREENING MARKET SIZE, BY PLASMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL BLOOD SCREENING MARKET SIZE, BY PLASMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL BLOOD SCREENING MARKET SIZE, BY SERUM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL BLOOD SCREENING MARKET SIZE, BY SERUM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL BLOOD SCREENING MARKET SIZE, BY SERUM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL BLOOD SCREENING MARKET SIZE, BY WHOLE BLOOD, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL BLOOD SCREENING MARKET SIZE, BY WHOLE BLOOD, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL BLOOD SCREENING MARKET SIZE, BY WHOLE BLOOD, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL BLOOD SCREENING MARKET SIZE, BY TESTING MODE, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL BLOOD SCREENING MARKET SIZE, BY LAB BASED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL BLOOD SCREENING MARKET SIZE, BY LAB BASED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL BLOOD SCREENING MARKET SIZE, BY LAB BASED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL BLOOD SCREENING MARKET SIZE, BY POINT OF CARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL BLOOD SCREENING MARKET SIZE, BY POINT OF CARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL BLOOD SCREENING MARKET SIZE, BY POINT OF CARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL BLOOD SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL BLOOD SCREENING MARKET SIZE, BY BLOOD BANKS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL BLOOD SCREENING MARKET SIZE, BY BLOOD BANKS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL BLOOD SCREENING MARKET SIZE, BY BLOOD BANKS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL BLOOD SCREENING MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL BLOOD SCREENING MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL BLOOD SCREENING MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL BLOOD SCREENING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL BLOOD SCREENING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL BLOOD SCREENING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL BLOOD SCREENING MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL BLOOD SCREENING MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL BLOOD SCREENING MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL BLOOD SCREENING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. AMERICAS BLOOD SCREENING MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 80. AMERICAS BLOOD SCREENING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 81. AMERICAS BLOOD SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 82. AMERICAS BLOOD SCREENING MARKET SIZE, BY IMMUNOASSAYS, 2018-2032 (USD MILLION)
  • TABLE 83. AMERICAS BLOOD SCREENING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 84. AMERICAS BLOOD SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 85. AMERICAS BLOOD SCREENING MARKET SIZE, BY TESTING MODE, 2018-2032 (USD MILLION)
  • TABLE 86. AMERICAS BLOOD SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 87. NORTH AMERICA BLOOD SCREENING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. NORTH AMERICA BLOOD SCREENING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 89. NORTH AMERICA BLOOD SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 90. NORTH AMERICA BLOOD SCREENING MARKET SIZE, BY IMMUNOASSAYS, 2018-2032 (USD MILLION)
  • TABLE 91. NORTH AMERICA BLOOD SCREENING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 92. NORTH AMERICA BLOOD SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 93. NORTH AMERICA BLOOD SCREENING MARKET SIZE, BY TESTING MODE, 2018-2032 (USD MILLION)
  • TABLE 94. NORTH AMERICA BLOOD SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 95. LATIN AMERICA BLOOD SCREENING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. LATIN AMERICA BLOOD SCREENING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 97. LATIN AMERICA BLOOD SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 98. LATIN AMERICA BLOOD SCREENING MARKET SIZE, BY IMMUNOASSAYS, 2018-2032 (USD MILLION)
  • TABLE 99. LATIN AMERICA BLOOD SCREENING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 100. LATIN AMERICA BLOOD SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 101. LATIN AMERICA BLOOD SCREENING MARKET SIZE, BY TESTING MODE, 2018-2032 (USD MILLION)
  • TABLE 102. LATIN AMERICA BLOOD SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA BLOOD SCREENING MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA BLOOD SCREENING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA BLOOD SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA BLOOD SCREENING MARKET SIZE, BY IMMUNOASSAYS, 2018-2032 (USD MILLION)
  • TABLE 107. EUROPE, MIDDLE EAST & AFRICA BLOOD SCREENING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPE, MIDDLE EAST & AFRICA BLOOD SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPE, MIDDLE EAST & AFRICA BLOOD SCREENING MARKET SIZE, BY TESTING MODE, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPE, MIDDLE EAST & AFRICA BLOOD SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPE BLOOD SCREENING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE BLOOD SCREENING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPE BLOOD SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPE BLOOD SCREENING MARKET SIZE, BY IMMUNOASSAYS, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE BLOOD SCREENING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPE BLOOD SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPE BLOOD SCREENING MARKET SIZE, BY TESTING MODE, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE BLOOD SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 119. MIDDLE EAST BLOOD SCREENING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. MIDDLE EAST BLOOD SCREENING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 121. MIDDLE EAST BLOOD SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 122. MIDDLE EAST BLOOD SCREENING MARKET SIZE, BY IMMUNOASSAYS, 2018-2032 (USD MILLION)
  • TABLE 123. MIDDLE EAST BLOOD SCREENING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 124. MIDDLE EAST BLOOD SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 125. MIDDLE EAST BLOOD SCREENING MARKET SIZE, BY TESTING MODE, 2018-2032 (USD MILLION)
  • TABLE 126. MIDDLE EAST BLOOD SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 127. AFRICA BLOOD SCREENING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 128. AFRICA BLOOD SCREENING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 129. AFRICA BLOOD SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 130. AFRICA BLOOD SCREENING MARKET SIZE, BY IMMUNOASSAYS, 2018-2032 (USD MILLION)
  • TABLE 131. AFRICA BLOOD SCREENING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 132. AFRICA BLOOD SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 133. AFRICA BLOOD SCREENING MARKET SIZE, BY TESTING MODE, 2018-2032 (USD MILLION)
  • TABLE 134. AFRICA BLOOD SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 135. ASIA-PACIFIC BLOOD SCREENING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 136. ASIA-PACIFIC BLOOD SCREENING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 137. ASIA-PACIFIC BLOOD SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 138. ASIA-PACIFIC BLOOD SCREENING MARKET SIZE, BY IMMUNOASSAYS, 2018-2032 (USD MILLION)
  • TABLE 139. ASIA-PACIFIC BLOOD SCREENING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 140. ASIA-PACIFIC BLOOD SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 141. ASIA-PACIFIC BLOOD SCREENING MARKET SIZE, BY TESTING MODE, 2018-2032 (USD MILLION)
  • TABLE 142. ASIA-PACIFIC BLOOD SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 143. GLOBAL BLOOD SCREENING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 144. ASEAN BLOOD SCREENING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 145. ASEAN BLOOD SCREENING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 146. ASEAN BLOOD SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 147. ASEAN BLOOD SCREENING MARKET SIZE, BY IMMUNOASSAYS, 2018-2032 (USD MILLION)
  • TABLE 148. ASEAN BLOOD SCREENING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 149. ASEAN BLOOD SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 150. ASEAN BLOOD SCREENING MARKET SIZE, BY TESTING MODE, 2018-2032 (USD MILLION)
  • TABLE 151. ASEAN BLOOD SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 152. GCC BLOOD SCREENING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 153. GCC BLOOD SCREENING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 154. GCC BLOOD SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 155. GCC BLOOD SCREENING MARKET SIZE, BY IMMUNOASSAYS, 2018-2032 (USD MILLION)
  • TABLE 156. GCC BLOOD SCREENING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 157. GCC BLOOD SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 158. GCC BLOOD SCREENING MARKET SIZE, BY TESTING MODE, 2018-2032 (USD MILLION)
  • TABLE 159. GCC BLOOD SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPEAN UNION BLOOD SCREENING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPEAN UNION BLOOD SCREENING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 162. EUROPEAN UNION BLOOD SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPEAN UNION BLOOD SCREENING MARKET SIZE, BY IMMUNOASSAYS, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPEAN UNION BLOOD SCREENING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPEAN UNION BLOOD SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPEAN UNION BLOOD SCREENING MARKET SIZE, BY TESTING MODE, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPEAN UNION BLOOD SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 168. BRICS BLOOD SCREENING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 169. BRICS BLOOD SCREENING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 170. BRICS BLOOD SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 171. BRICS BLOOD SCREENING MARKET SIZE, BY IMMUNOASSAYS, 2018-2032 (USD MILLION)
  • TABLE 172. BRICS BLOOD SCREENING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 173. BRICS BLOOD SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 174. BRICS BLOOD SCREENING MARKET SIZE, BY TESTING MODE, 2018-2032 (USD MILLION)
  • TABLE 175. BRICS BLOOD SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 176. G7 BLOOD SCREENING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 177. G7 BLOOD SCREENING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 178. G7 BLOOD SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 179. G7 BLOOD SCREENING MARKET SIZE, BY IMMUNOASSAYS, 2018-2032 (USD MILLION)
  • TABLE 180. G7 BLOOD SCREENING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 181. G7 BLOOD SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 182. G7 BLOOD SCREENING MARKET SIZE, BY TESTING MODE, 2018-2032 (USD MILLION)
  • TABLE 183. G7 BLOOD SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 184. NATO BLOOD SCREENING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 185. NATO BLOOD SCREENING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 186. NATO BLOOD SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 187. NATO BLOOD SCREENING MARKET SIZE, BY IMMUNOASSAYS, 2018-2032 (USD MILLION)
  • TABLE 188. NATO BLOOD SCREENING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 189. NATO BLOOD SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 190. NATO BLOOD SCREENING MARKET SIZE, BY TESTING MODE, 2018-2032 (USD MILLION)
  • TABLE 191. NATO BLOOD SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 192. GLOBAL BLOOD SCREENING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 193. UNITED STATES BLOOD SCREENING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 194. UNITED STATES BLOOD SCREENING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 195. UNITED STATES BLOOD SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 196. UNITED STATES BLOOD SCREENING MARKET SIZE, BY IMMUNOASSAYS, 2018-2032 (USD MILLION)
  • TABLE 197. UNITED STATES BLOOD SCREENING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 198. UNITED STATES BLOOD SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 199. UNITED STATES BLOOD SCREENING MARKET SIZE, BY TESTING MODE, 2018-2032 (USD MILLION)
  • TABLE 200. UNITED STATES BLOOD SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 201. CHINA BLOOD SCREENING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 202. CHINA BLOOD SCREENING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 203. CHINA BLOOD SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 204. CHINA BLOOD SCREENING MARKET SIZE, BY IMMUNOASSAYS, 2018-2032 (USD MILLION)
  • TABLE 205. CHINA BLOOD SCREENING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 206. CHINA BLOOD SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 207. CHINA BLOOD SCREENING MARKET SIZE, BY TESTING MODE, 2018-2032 (USD MILLION)
  • TABLE 208. CHINA BLOOD SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)